Stockscreener 앱 받기
0.11%
시장 영업 전:
전일 마감가:
$317.38
열려 있는:
$317.3
하루 거래량:
2.19M
Relative Volume:
0.83
시가총액:
$171.10B
수익:
$35.89B
순이익/손실:
$7.01B
주가수익비율:
24.56
EPS:
12.9352
순현금흐름:
$11.54B
1주 성능:
-3.68%
1개월 성능:
-5.51%
6개월 성능:
+6.88%
1년 성능:
+15.94%
1일 변동 폭
$315.19
$319.46
1주일 범위
$312.38
$329.67
52주 변동 폭
$253.30
$346.38
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
AMGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
317.74 | 170.90B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-11-24 | 재개 | Truist | Hold |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
B. Riley Wealth Advisors Inc. Invests $1.65 Million in Amgen Inc. $AMGN - MarketBeat
Advisory Services Network LLC Grows Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025 - ts2.tech
Amgen’s New Study on Maridebart Cafraglutide: A Potential Game-Changer in Obesity Treatment? - TipRanks
Amgen’s New Phase 3 Trial: A Potential Game-Changer for Obstructive Sleep Apnea Treatment - TipRanks
Provident Investment Management Inc. Invests $1.29 Million in Amgen Inc. $AMGN - MarketBeat
Thrivent Financial for Lutherans Increases Position in Amgen Inc. $AMGN - MarketBeat
MASTERINVEST Kapitalanlage GmbH Invests $2.77 Million in Amgen Inc. $AMGN - MarketBeat
Neuberger Berman Group LLC Grows Position in Amgen Inc. $AMGN - MarketBeat
Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year - Yahoo Finance
Rexford Capital Inc. Purchases New Shares in Amgen Inc. $AMGN - MarketBeat
China Universal Asset Management Co. Ltd. Has $16.87 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. - The Motley Fool
Coppell Advisory Solutions LLC Has $1.36 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Assessing Amgen (AMGN)’s Valuation After FDA Approval of Uplizna for Generalized Myasthenia Gravis - simplywall.st
Treasurer of the State of North Carolina Boosts Stake in Amgen Inc. $AMGN - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Has $23.15 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Bellevue Group AG Sells 56,827 Shares of Amgen Inc. $AMGN - MarketBeat
Banque Transatlantique SA Sells 141,712 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen’s Uplizna Approved For Its Largest And Most Competitive Indication Yet - Citeline News & Insights
FDA Grants Orphan Status to Amgen's (AMGN) Blinatumomab for Leuk - GuruFocus
Amgen (AMGN) Receives Maintained Rating, Price Target Lowered to - GuruFocus
FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease - Yahoo Finance
FDA Approves Amgen's Drug For Rare Muscle Disorder - Benzinga
Amgen (AMGN) Gains FDA Nod for Expanded Use of Uplizna in Myasth - GuruFocus
Morgan Stanley Adjusts Amgen Price Target to $304 From $329, Maintains Equalweight Rating - marketscreener.com
Amgen wins FDA nod for Uplizna in myasthenia gravis (AMGN) - Seeking Alpha
Quantinno Capital Management LP Purchases 19,014 Shares of Amgen Inc. $AMGN - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Lowers Holdings in Amgen Inc. $AMGN - MarketBeat
Peapack Gladstone Financial Corp Has $30.82 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Sei Investments Co. - MarketBeat
Amgen Says FDA Approves Uplizna For Autoimmune Disorder Treatment - marketscreener.com
FDA approves Amgen’s UPLIZNA for generalized myasthenia gravis - Investing.com
FDA Approves Amgen's UPLIZNA for New Myasthenia Gravis Treatment - GuruFocus
FDA approves Amgen’s UPLIZNA for generalized myasthenia gravis By Investing.com - Investing.com Australia
Amgen (NASDAQ:AMGN) gets FDA OK for Uplizna as first CD19 B-cell therapy for gMG - Stock Titan
The Manufacturers Life Insurance Company Reduces Position in Amgen Inc. $AMGN - MarketBeat
NewEdge Advisors LLC Grows Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Wells Fargo Maintains Amgen (AMGN) Equal-Weight Recommendation - Nasdaq
Amgen Inc. (NASDAQ:AMGN) Announces Quarterly Dividend of $2.52 - MarketBeat
Amgen describes new GTPase KRAS mutant inhibitors - BioWorld MedTech
Amgen: Improving Balance Sheet Is Bringing The Stock Close To Being A "Buy" (NASDAQ:AMGN) - Seeking Alpha
Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Intact Investment Management Inc. Sells 10,800 Shares of Amgen Inc. $AMGN - MarketBeat
Ossiam Sells 13,818 Shares of Amgen Inc. $AMGN - MarketBeat
Wells Fargo Adjusts Price Target on Amgen to $325 From $300, Maintains Equalweight Rating - marketscreener.com
HSBC Adjusts Price Target on Amgen to $425 From $381, Maintains Buy Rating - marketscreener.com
Amgen (AMGN) to Participate in Upcoming Virtual Meeting - GuruFocus
Amgen Announces Dividend for the First Quarter of 2026, Payable on March 6, 2026 - marketscreener.com
Amgen Raises Quarterly Dividend to $2.52 a Share From $2.38, Payable March 6 to Shareholders of Record as of Feb. 13 - marketscreener.com
Amgen declares $2.52 per share dividend for first quarter 2026 By Investing.com - Investing.com UK
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.28%
0.19%
자본화:
|
볼륨(24시간):